https://www.selleckchem.com/pr....oducts/birinapant-tl
orbidity and mortality. These findings should help clinicians balance the risks and benefits of transfusion before well-designed trials are conducted in this patient population. Despite novel therapies, multiple myeloma (MM) remains an incurable malignancy, daratumumab (DARA) being a major game changer, may be a good option for treatment. To assess the prescription patterns of DARA in patients with MM in Mexico. 47 patients with MM were analyzed in 13 different hospitals in Mexico. Five (10.5%) of patients received DARA as fi
Mi piace
Commento
Condividi
